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Interleukin 6 (IL-6) and its soluble receptor (IL-6sR) can markedly stimulate aromatase activity in cultured fibroblasts derived from
normal or malignant breast tissues. IL-6 acts by binding to a low-affinity membrane-spanning receptor (IL-6R), which must associate
with a high-affinity receptor (gp130) for signal transduction to occur. Sant 7 is a mutated form of IL-6 that can bind to the IL-6R, but
inhibits its ability to interact with the gp130 signal transducing protein. In this study, we have used Sant 7 to examine its ability to
inhibit IL-6+IL-6 soluble receptor (IL-6sR)-stimulated aromatase activity in breast tissue-derived fibroblasts. As previously observed,
IL-6+IL-6sR markedly stimulated aromatase activity (7.7–20.8-fold) in fibroblasts derived from reduction mammoplasty tissue, tissue
proximal to tumours and breast tumours. Sant 7 inhibited basal aromatase activity in some fibroblasts by 25–30% that had a high
basal activity, but almost completely blocked the ability of IL-6+IL-6sR to stimulate aromatase activity. The IC50 for the inhibition of IL-
6+IL-6sR-stimulated aromatase activity by Sant 7 was 60ngml
 1. A comparison of the effects of prostaglandin E2 (PGE2), which can
also regulate aromatase activity, and IL-6+IL-6sR revealed a greater degree of aromatase stimulation by IL-6+IL-6sR. Sant 7, however,
inhibited PGE2-stimulated aromatase activity by 70% suggesting that PGE2 acts, in part, by stimulating IL-6 production. Much of the IL-
6 and IL-6sR available to stimulate breast tumour aromatase activity may originate from infiltrating macrophages and lymphocytes.
The ability to block aromatase stimulation by these factors may offer a novel therapeutic strategy for reducing oestrogen synthesis in
breast tumours.
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A number of potent aromatase inhibitors have now been
introduced for use in postmenopausal women with hormone-
dependent breast tumours (Miller, 1999). While their development
represents an important advance in the therapies available for the
treatment of women with breast cancer, the complete and partial
response rates, when used as second-line therapy, remain relatively
low (10–20%) with the time to tumour progression being relatively
short (3–6 months) (Santen and Harvey, 1999). However, in a
recent trial into the adjuvant use of an aromatase inhibitor vs
tamoxifen, alone or in combination, disease-free survival was
significantly longer for subjects receiving aromatase inhibitor
therapy (ATAC Trialist Group, 2002). In addition, a number of
adverse side effects, including gastrointestinal problems, dizziness
and nausea, are associated with the use of some of the inhibitors
(Buzdar et al, 1997). The use of aromatase inhibitors in
postmenopausal women with breast cancer has also been reported
to have an unfavourable effect on the serum lipid profile (Elisaf
et al, 2001). There is, therefore, a need to develop new methods of
inhibiting aromatase activity that may act specifically within the
breast but spare other oestrogen-sensitive tissues.
The aromatase enzyme complex, which converts androstene-
dione to oestrone, has a pivotal role in controlling oestrogen
synthesis in peripheral tissues in postmenopausal women. The
enzyme is present not only in adipose tissue but also in normal
and malignant breast tissues (James et al, 1987). Previous studies
have revealed that the expression of the aromatase gene is
regulated in a tissue-specific manner by the use of a number of
different promoters (Mahendroo et al, 1993; Zhao et al, 1995a,b).
In adipose tissue expression is regulated by promoter PI.4. The
50-upstream region of this promoter contains a glucocortcoid
response element and a GAS (IFNg activating sequence) element,
which can bind transcription factors of the signal transducer and
activation of transcription (STAT) family (Zhao et al, 1995a,b).
Cytokines in the presence of glucocorticoids regulate gene
expression via PI.4. Promoter switching may occur in malignant
breast tissues with an increase in the levels of PII and PI.3 being
detected (Harada et al, 1993; Agarwal et al, 1996). Expression of
the aromatase gene via PII and PI.3 is regulated by cyclic AMP
(cAMP) and there is evidence that prostaglandin E2 (PGE2) may be
the major factor regulating expression via these promoters (Zhao
et al, 1996). Evidence has been obtained, however, to suggest that
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sPGE2 may act, at least in part, to stimulate aromatase activity by
induction of IL-6 (Zhang et al, 1988; Hinson et al, 1996).
Fibroblasts derived from normal or malignant breast tissues
have been used as a model to investigate aromatase activity as
these cells have a much higher level of activity than epithelial cells
(Singh et al, 1999). Using such fibroblasts a number of cytokines
including interleukin 6 (IL-6) and tumour necrosis factor a (TNFa)
were identified as important regulators of fibroblast aromatase
activity (Reed et al, 1992; Macdiarmid et al, 1994). Peripheral
aromatase activity is increased in elderly and obese subjects
(Grodin et al, 1973; Hemsell et al, 1974) and production of IL-6 is
also increased in these conditions (Wei et al, 1992; Mohamed-Ali
et al, 1997).
The ability of IL-6 to stimulate aromatase activity in cultured
fibroblasts is markedly potentiated (up to 21-fold) by its soluble
receptor, IL-6sR (Singh et al, 1995; Zhao et al, 1995a,b). IL-6 is
produced by fibroblasts derived from normal and malignant breast
tissues, whereas IL-6sR was only detected in conditioned medium
collected from malignant fibroblasts (Singh et al, 1995). Many
breast tumours are infiltrated by macrophages and lymphocytes
and there is evidence that these cells may be a major source of
factors that are able to stimulate aromatase activity within the
breast (Purohit et al, 1995; Reed and Purohit, 1997).
Like other cytokines IL-6 acts by binding to a membrane-
spanning receptor. The IL-6R complex consists of an 80kDa
(gp80) ligand-binding subunit and a 130kDa (gp130) signal-
transducing protein (Taga et al, 1989; Kishimoto et al, 1995). The
gp80 subunit, which can also exist in a soluble form (Rose-John
and Heinrich, 1994), binds IL-6 with low affinity and must
associate with the larger gp130 for high affinity binding and signal
transduction to occur. While IL-6 monoclonal antibodies (Mabs)
have been used to abrogate the effects of IL-6, they are only
partially effective (Klein et al, 1991). The Mabs form a complex
with IL-6, which results in reduced clearance of the cytokine.
As an alternative approach to block the actions of IL-6 Ciliberto
and colleagues generated a number of IL-6 receptor antagonists,
which were mutated forms of IL-6, that can bind to the IL-6R but
block it in an inactive configuration (Demartis et al, 1996). This
inhibits its ability to interact with the gp130 signal-transducing
protein. The IL-6 variant Sant 7 was identified as the most potent
superantagonist and it was able to inhibit the IL-6-stimulated
growth of several different malignant cell types. In view of the
important role that IL-6+IL-6sR have in regulating aromatase
activity, the ability of Sant 7 to block cytokine-stimulated
aromatase activity has been investigated. Sant 7 was also employed
to obtain further information about the process by which PGE2
regulates aromatase activity in breast tissue-derived fibroblasts.
MATERIALS AND METHODS
Culture of fibroblasts
Samples of breast adipose tissue were collected from women
undergoing reduction mammoplasty. In addition, samples of
breast adipose tissue proximal to breast tumours (i.e. ‘non-
involved’ tissue) and breast tumours were collected from women
undergoing lumpectomy or mastectomy. Tissue samples were
collected after obtaining subjects’ informed consent to the study,
which was approved by the hospital Ethics Committee.
Resected tissues were minced with scalpels and incubated in
Eagles’ modified minimum essential medium (EMEM) for 18–24h
at 371 with collagenase (200mgml
 1). The dispersed cells were
harvested by centrifugation and washed twice with medium to
remove collagenase. Dispersed cells were seeded into 25cm
2
culture flasks and allowed to attach. Cells were grown to
confluence in EMEM containing HEPES buffer (20mmoll
 1),
10% fetal calf serum (FCS) and supplements (Reed et al, 1992).
Cells were routinely passaged two to three times after which
replicate 25cm
2 culture flasks were seeded and grown to 70–80%
confluency. The medium was replaced with 2%c. charcoal-stripped
FCS, phenol red-free EMEM and treatments were added in this
medium for 48h in the presence of dexamethasone (100nM) and
included: IL-6+IL-6sR (50 and 100ngml
 1, R&D Systems Ltd,
Abingdon, Oxon, UK) and PGE2 (10mM, Sigma, Poole, Dorset, UK).
Sant 7
The IL-6R superantagonist Sant 7 was obtained from Sigma-Tau
(Rome, Italy) and synthesised as previously described (Salvati et al,
1995). Sant 7 was dissolved in culture medium before adding to
cells.
Aromatase assay
Aromatase activity was measured in intact fibroblast monolayers
using (1b-
3H) androstenedione (15–30Cimmol
 1, NEN- Du Pont,
Stevenage, Herts, UK) over a 3–20h period (Reed et al, 1992).
Briefly, fibroblast monolayers were washed once with Earle’s
balanced salt solution EM (2.5ml) unless stated otherwise. To each
flask
3H androstenedione (0.25mCi) was added to give a final
substrate concentration of 3–4nM. Fibroblast monolayers were
incubated with substrate for 3–20h at 371C depending on the basal
aromatase activity in the cells. Flasks containing no cells were also
incubated with substrate and serum-free medium as assay blanks.
After incubation, an aliquot of medium (2ml) was removed from
each flask and aliquots were extracted twice with diethylether
(5ml), which was discarded. The remaining aqueous phase was
treated with an equal volume of a solution containing charcoal
(5.0%) and dextran (0.5%), centrifuged and an aliquot of the
supernatant (1ml) was taken to determine its radioactive content
by liquid scintillation spectrometry. It has previously been
established that aromatase activity, as measured in fibroblasts, is
linear with respect to time for up to 24h (Macdiarmid et al, 1994).
Statistics
The significance of differences in aromatase activity in treated and
control cells was assessed using Student’s t-test. Representative
example of results are shown for experiments that were repeated
2–3 times.
RESULTS
The ability of Sant 7 to inhibit cytokine-stimulated aromatase
activity was initially examined in fibroblasts derived from breast
adipose tissue of a subject undergoing reduction mammoplasty
(Figure 1). In these fibroblasts, IL-6 alone, (at 50ngml
 1)
increased aromatase activity by 27%. The addition of IL-6sR in
combination with IL-6, however, markedly potentiated its ability to
stimulate aromatase activity (7.7-fold compared with controls).
Sant 7 caused a significant (Po0.05) decrease in basal aromatase
activity and IL-6-stimulated activity (Po0.001). Sant 7 was able to
almost completely block the ability of IL-6+IL-6sR to stimulate
aromatase activity. In a further series of experiments, the ability of
Sant 7 to block cytokine-stimulated aromatase activity in
fibroblasts derived from tissue proximal to a tumour (proximal
fibroblasts) and also the tumour (tumour fibroblasts) from the
same subject was examined (Figures 2A and B). In the presence of
dexamethasone, basal aromatase activity was 10 times higher in
proximal fibroblasts than in tumour fibroblasts. The extent to
which IL-6+IL-6sR-stimulated aromatase was also greater in
proximal fibroblasts (20.8-fold) than in tumour fibroblasts
(7.9-fold). No apparent differences were detected in the cellular
homogeneity or viability of fibroblasts derived from tumour or
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in basal and IL-6+IL-6sR-stimulated aromatase activity in these
different fibroblasts. In both types of fibroblasts Sant 7 completely
blocked IL-6+IL-6sR stimulation of aromatase activity. Preincuba-
tion of proximal fibroblasts with Sant 7, prior to the addition of IL-
6+IL-6sR, did not increase its ability to block aromatase
stimulation (Figure 2A). A dose–response study was carried out
using proximal fibroblasts. The IC50 was calculated as the
concentration of Sant 7 that inhibited IL-6+IL-6sR-stimulated
aromatase activity by 50% and was 60ngml
 1 (Figure 3).
To examine if dexamethasone was an absolute requirement for
the ability of Sant 7 to block IL-6+IL-6sR-induced aromatase
activity, an experiment was carried out in the absence or presence
of this glucocorticoid (Figure 4). As shown, a similar pattern of
responses to IL-6, IL-6sR or Sant 7, alone or in combination was
seen in the absence or presence of dexamethasone. However, the
extent of simulation by IL-6+IL-6sR was considerably greater
(772%) in its presence than in its absence (252%). Sant 7 did
inhibit the IL-6+IL-6sR-induced aromatase activity in the absence
of dexamethasone.
The regulation of aromatase gene expression is complex and
controlled by factors such as PGE2 and IL-6 (Mahendroo et al,
1993). There is evidence, however, that PGE2 may act, in part, to
stimulate aromatase activity by the induction of IL-6 (Singh et al,
1999). As Sant 7 effectively blocks stimulation of aromatase activity
by IL-6+IL-6sR, it was used to obtain further insight into its
regulation by IL-6 or PGE2. In proximal and tumour fibroblasts,
derived from the same subject, PGE2 stimulated aromatase activity
by 521 and 103%, respectively (Figures 5A and B). The
combination of IL-6+IL-6sR was considerably more potent at
simulating activity in proximal and tumour fibroblasts than PGE2,
by 9.6– and 7.1-fold, respectively. In these fibroblasts Sant 7 itself
inhibited basal aromatase activity by 30%. Sant 7 reduced the
ability of PGE2 to stimulate aromatase activity in proximal and
tumour fibroblasts by 69 and 75%, respectively. In these
experiments the ability of Sant 7 to act in a reversible or
irreversible manner was also examined (Figures 4A and B).
Fibroblasts were preincubated for 12h with Sant 7, after which it
was removed from the cells by washing with phosphate-buffered
saline. Subsequent addition of IL-6+IL-6sR showed that they were
able to stimulate aromatase activity indicating that Sant 7 did not
bind to the IL-6R in an irreversible manner.
DISCUSSION
The results obtained from these studies have confirmed previous
findings that IL-6+IL-6sR can markedly stimulate aromatase
activity in breast tissue-derived fibroblasts (Singh et al, 1995;
Zhao et al, 1995a,b). The potentiation by IL-6sR of the IL-6
stimulation of aromatase activity presumably results from an
increase in the interaction of the IL-6–IL-6sR complex with the
gp130 signal-transduction protein. In some cell systems the
6000
5000
4000
3000
2000
1000
0
Control IL-6
50
ng ml
_1
IL-6sR
100
ng ml
_1
Sant 7
10
g ml
_1
IL-6 
+ 
IL-6sR
IL-6
+ 
Sant 7
IL-6 + 
IL-6sR
+ Sant 7
A
r
o
m
a
t
a
s
e
 
a
c
t
i
v
i
t
y
 
(
f
m
o
l
 
2
0
 
h
_
1
 
1
0
6
 
c
e
l
l
s
_
1
)
a
b c
a
d
Figure 1 Effect of the IL-6 receptor superantagonist, Sant 7, on IL-6, IL-
6sR or IL-6+IL-6sR-stimulated aromatase activity in fibroblasts derived from
reduction mammoplasty breast adipose tissue. Fibroblasts were cultured in
2% stripped FCS, phenol red-free EMEM and treatments were added in this
medium for 48h in the presence of dexamethasone (100nM). Aromatase
activity was measured in intact fibroblast monolayers using [
3H-1b]andros-
tenedione as the substrate. The significance of differences in treated and
control cells was assessed using Student’s t-test (a, Po0.001 vs controls; b,
Po0.05 vs controls; c, Po0.001 vs IL-6; d, Po0.001 vs IL-6+IL-6sR,
means7s.d., n¼3).
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Figure 2 (A) Effect of Sant 7 on IL-6, IL-6sR or IL-6+IL-6sR-stimulated
aromatase activity in fibroblasts derived from tissue proximal to a breast
tumour. Fibroblasts were cultured in 2% stripped FCS, phenol red-free
EMEM and treatments were added in this medium for 48h in the presence
of dexamethasone (100nM). Aromatase activity was measured in intact
monolayers using [
3H-1b]androstenedione as the substrate. One set of
cells (pretreatment) was preincubated with Sant 7 for 3h before the
addition of IL-6+IL-6sR, while for another set (no pretreatment) Sant 7
was added at the same time as IL-6+IL-6sR (a, Po0.001 vs controls; b,
Po0.001 vs IL-6+IL-6sR, means7s.d., n¼3). (B) Effect of Sant 7 on IL-6
or IL-6+IL-6sR-stimulated aromatase activity in fibroblasts derived from a
breast tumour. Culture conditions were as described above (a, Po0.001 vs
controls; b, Po0.001 vs IL-6+IL-6sR, means7s.d., n¼3).
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scombination of IL-6+dexamethasone can markedly upregulate the
expression of gp130 mRNA (Schooltink et al, 1992). In a previous
study, the ability of Sant 7 to inhibit the proliferation of multiple
myeloma cells was found to be dependent upon the presence of
dexamethasone and retinonic acid (Honemann et al, 2001). This
was not the case in the present study where Sant 7 was able to
inhibit IL-6+IL-6sR-induced aromatase activity in the absence of
glucocorticoid. The ability of IL-6+IL-6sR to stimulate aromatase
activity was almost completely blocked by Sant 7 in all the
fibroblasts examined. Sant 7 is a mutated form of IL-6 that binds to
the IL-6R with an increased affinity that results in an inactive
configuration of the receptor (Demartis et al, 1996). In addition to
blocking cytokine-stimulated aromatase activity, Sant 7 also
reduced the basal activity of this enzyme in some fibroblasts that
had a relatively high basal activity, by up to 30%. It has previously
been shown that breast tissue-derived fibroblasts can secrete IL-6
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Figure 3 Dose response for the ability of Sant 7 to inhibit IL-6+IL-6sR-
stimulated aromatase in fibroblasts derived from tissue proximal to a breast
tumour. Sant 7 inhibited the stimulated aromatase activity with an IC50 of
60ngml
 1 (means of triplicate measurements for which the coefficients of
variation were o10%).
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Figure 4 Ability of Sant 7 to inhibit IL-6+IL-6 sR stimulation of
aromatase activity in fibroblasts derived from reduction mammoplasty
tissue. Cells were treated for 48h with IL-6 (50ngml
 1), IL-6sR
(100ngml
 1) or Sant 7 (10mgml
 1), or in combinations as shown, in
the absence or presence of dexamethasone (Dex, 100nM). Aromatase
activity in control cells was 1370715fmol20 h
 110
6cells
 1 and
639735fmol20 h
 110
6 cells
 1 for fibroblasts cultured in the absence
or presence of dexamethasone (means7s.d., n¼3; a, Po0.05 vs controls;
b, Po0.001 vs controls; NS, not significant).
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Figure 5 (A) Effect of Sant 7 on PGE2-stimulated aromatase in proximal
fibroblasts. IL-6 (50ngml
 1)+IL-6sR (100ngml
 1) stimulated aromatase
activity to a greater extent than did PGE2 (10mM). Sant 7, which blocks IL-
6+IL-6sR-stimulated aromatase activity, significantly reduced the ability of
PEG2 to stimulate aromatase activity in these fibroblasts. To examine if the
effects of Sant 7 were reversible (Rev), one set of fibroblasts (IL-6+IL-6sR
(Rev)) was preincubated with Sant 7 for 12h and then Sant 7 was removed
by washing the cells with phosphate-buffered saline. IL-6+IL-6sR stimulated
aromatase activity in these cells after washing to a similar extent to
fibroblasts not exposed to Sant 7, showing that Sant 7 does not act in an
irreversible manner. (a, Po0.001 vs controls; b, Po0.0001 vs PGE2;c ,
Po0.001 PGE2+Sant 7 vs PGE2). (B) As for the legend to Figure 4A but
carried out using breast tumour-derived fibroblasts (a, Po0.001 vs controls;
b, Po0.001 vs PGE2;c ,Po0.05 vs controls; d, Po0.001 vs PGE2,
means7s.d., n¼3).
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s(Purohit et al, 1995). The finding that Sant 7 can reduce basal
aromatase activity in these cells suggests that the IL-6 they produce
is able to act in an autocrine/paracine manner to increase
aromatase activity.
In related studies into the control of aromatase activity, the
ability of a number of 10–16 amino-acid peptides to inhibit
IL-6+IL-6sR-stimulated aromatase activity was previously exam-
ined (Parish et al, 2001). The 16 amino-acid peptide, AROHIB, at
10mM inhibited the ability of these cytokines to stimulate
aromatase activity by 65%. AROHIB is therefore a less potent
inhibitor of IL-6+IL-6sR-stimulated aromatase activity than Sant 7.
Furthermore, to be effective it was necessary to preincubate cells
with AROHIB prior to the addition of IL-6+IL-6sR. For Sant 7 no
preincubation period was found to be necessary. Sant 7, however,
does not bind to the IL-6R in an irreversible manner as
preincubation of fibroblasts followed by washing with phos-
phate-buffered saline restored the ability of IL-6+IL-6sR to
stimulate aromatase activity.
There is now good evidence that malignant fibroblasts produce
IL-6 and IL-6sR and that tumour infiltrating macrophages
and lymphocytes may also be an important source of factors
that can stimulate oestrogen synthesis in breast tumours
(Purohit et al, 1995; Singh et al, 1997). If IL-6 and IL-6sR, derived
from these cells, are important regulators of aromatase activity,
then the use of Sant 7 may offer a means of selectively blocking
aromatase stimulation within the breast. Although small molecule-
based aromatase inhibitors are being used for breast cancer
therapy they can only be used in postmenopausal women. Their
use in premenopausal women results in increased gonadotrophin
production that overcomes the aromatase blockage. Thus, the
ability to inhibit cytokine-stimulated aromatase activity in breast
tissues of premenopausal women, either in the preventive or
therapeutic setting, could be an important option for the use of
Sant 7.
In addition to cytokines stimulating aromatase activity, PGE2
has also been implicated in the control of this enzyme (Zhao et al,
1996). However, determining the extent of regulation of aromatase
activity by PGE2 in fibroblasts is complicated by the finding that
PGE2, or factors that can increase intracellular cAMP levels, can
stimulate IL-6 secretion by cells (Zhang et al, 1988; Hinson et al,
1996). Sant 7 was therefore employed in an attempt to determine
whether PGE2 acts to stimulate aromatase activity by induction of
IL-6. It was reasoned that if PGE2 is acting by the induction of IL-6,
then Sant 7 should block, or reduce, its ability to stimulate
aromatase activity. It has previously been shown that the ability of
PGE2 to stimulate aromatase activity in breast tissue-derived
fibroblasts is associated with a significant increase in IL-6
production by these cells (Singh et al, 1997). As consistently
observed in previous studies, the ability of PGE2 to stimulate
aromatase activity in proximal and tumour fibroblasts (520 and
100%, respectively) was considerably lower than that achieved with
IL-6+IL-6sR (960 and 710%, respectively). Sant 7 reduced the PGE2
stimulation of aromatase activity by 69 and 75% in proximal
and tumour fibroblasts, respectively. As Sant 7 only blocks
IL-6-stimulated activity, this important finding indicates that a
major part of the ability of PGE2 to stimulate aromatase activity
results from its effect on IL-6 production.
IL-6 is a pleiotropic cytokine that has a number of important
physiological functions (Van Snick, 1990). Excess production is
associated with a number of pathological conditions including
multiple myeloma (Ludwig et al, 1991). IL-6 is also known to have
a role in regulating androgen receptor expression in an androgen-
independent manner (Chen et al, 2000). As a result it may be
involved in making prostate tumours resistant to endocrine
therapy (Lin et al, 2001). By blocking the action of IL-6, Sant 7
has been shown to potentiate the sensitivity of the hormone-
dependent prostate carcinoma cell line PC-3 to the cytotoxic effects
of etoposide and cisplatin (Borsellino et al, 1999). The develop-
ment of IL-6R superantagonists should allow the role of IL-6 in
hormone-dependent and -independent conditions, such as breast
and prostate cancer, to be elucidated and may lead to their use as
novel therapeutic options for their treatment.
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